GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Net Current Asset Value

4SC AG (FRA:VSC) Net Current Asset Value : €0.07 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is 4SC AG Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

4SC AG's net current asset value per share for the quarter that ended in Jun. 2024 was €0.07.

The historical rank and industry rank for 4SC AG's Net Current Asset Value or its related term are showing as below:

FRA:VSC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.22   Med: 4.83   Max: 133.2
Current: 119.6

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of 4SC AG was 133.20. The lowest was 2.22. And the median was 4.83.

FRA:VSC's Price-to-Net-Current-Asset-Value is ranked worse than
98.79% of 994 companies
in the Biotechnology industry
Industry Median: 3.915 vs FRA:VSC: 119.60

4SC AG Net Current Asset Value Historical Data

The historical data trend for 4SC AG's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Net Current Asset Value Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.51 3.14 2.40 1.18 0.44

4SC AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.18 0.76 0.44 0.07

Competitive Comparison of 4SC AG's Net Current Asset Value

For the Biotechnology subindustry, 4SC AG's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where 4SC AG's Price-to-Net-Current-Asset-Value falls into.



4SC AG Net Current Asset Value Calculation

4SC AG's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(8.754-4.351-0-0)/10.114
=0.44

4SC AG's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4.894-4.191-0-0)/10.114
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG  (FRA:VSC) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


4SC AG Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of 4SC AG's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG Business Description

Industry
Traded in Other Exchanges
Address
Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG Headlines

No Headlines